Who Should Not Take Wegovy For Weight Loss

Understanding Wegovy and Its Uses

Wegovy, a breakthrough medication in chronic weight management, offers hope for individuals struggling with obesity or overweight conditions alongside weight-related comorbidities (1,2). The FDA approved Wegovy for adults and pediatric patients aged 12 years and older with specific BMI criteria. It is an adjunct to a reduced-calorie diet and increased physical activity (3).

The active ingredient in Wegovy, semaglutide, mimics a hormone that targets areas of the brain involved in appetite regulation, thereby reducing hunger and calorie intake (1). For many, it represents a significant advancement in treating obesity, providing an additional tool for managing weight effectively.

Medical Conditions Contraindicating Wegovy Use

Despite its efficacy, not everyone is a candidate for Wegovy treatment. It is contraindicated in individuals with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Patients who have experienced severe hypersensitivity reactions to semaglutide or any of the excipients in Wegovy

Understanding these contraindications is imperative to avoid potentially life-threatening risks and ensure patient safety (3).

Potential Side Effects and Who's at Risk

Like all medications, Wegovy carries the risk of side effects. Some are mild and subside over time. Users generally experience different side effects, with nausea, vomiting, diarrhea, headache, and abdominal pain being among the most commonly reported side effects (1,2,6). Other side effects are extremely rare but severe. Patients must watch for signs of severe conditions and speak to their provider immediately.

Patients with existing health conditions should consult their healthcare provider to assess the balance between Wegovy's benefits and potential risks. The following are rare side effects that may be associated with Wegovy:

• Thyroid C-cell tumors: Semaglutide (the primary active ingredient in Wegovy)  has been shown to cause thyroid tumors and cancer in rodents. However, it’s unknown if semaglutide causes thyroid tumors and cancer in humans (3,4,5).  Human studies have not shown increased risk, but it’s essential to be aware when prescribing Wegovy to new patients (5).
• Acute pancreatitis: Sudden inflammation of the pancreas typically characterized by severe abdominal pain, nausea, and vomiting. It’s often triggered by gallstones or excessive alcohol consumption. However, acute pancreatitis has occurred in clinical trials among patients on semaglutide (3). Patients should watch for signs of severe abdominal pain and discontinue promptly Wegovy if pancreatitis is suspected. 
• Gallbladder disease: The use of semaglutide has been associated with reports of gallstones during clinical trials. Gallstones can cause right-sided upper abdominal pain, nausea, vomiting, yellowing of the skin, fevers, and chills (3). Talk with your doctor if gallstones are suspected.
• Hypoglycemia: Otherwise known as low blood sugar, hypoglycemia can be very serious and needs to be treated promptly. The risk of developing low blood sugar on Wegovy is particularly high when combined with insulin or insulin secretagogues(3).
• Acute kidney injury and gastrointestinal issues: Regular monitoring is essential when starting doses of Wegovy, especially in patients experiencing gastrointestinal symptoms such as vomiting or diarrhea, which can both lead to dehydration and stress on the kidneys (3).
• Diabetic Retinopathy: Patients with a history of diabetic retinopathy, a condition that affects type 2 diabetics and can lead to vision loss, should be monitored regularly if starting on Wegovy.

Alternatives to Wegovy for Those Who Should Avoid It

If Wegovy is unsuitable for a specific individual due to its contraindications or potential side effects, alternative weight management strategies and medications exist. These include:

• Other weight loss medications outside of the GLP-1 receptor agonist class 
• Traditional weight management approaches like lifestyle modification programs focusing on diet and physical activity
• Investigating newer pharmaceutical treatments that might suit different profiles of obesity and related conditions

Choosing the suitable alternative involves a detailed conversation with healthcare providers, considering individual health conditions, weight management goals, and each option's potential benefits and risks.

Explore other medications here: https://joinmochi.com/medications 

‍

Who is a Good Candidate for Wegovy?

Wegovy is designed for individuals looking for effective treatment in their fight against obesity and overweight issues, particularly when accompanied by weight-related health concerns such as hypertension, type 2 diabetes, and high cholesterol (1,2,3). Ideal candidates are adults and pediatric patients aged 12 years and older who meet specific BMI criteria and have not achieved sufficient weight loss through diet and exercise alone.

To consider Wegovy, patients should not have any of the contraindications mentioned earlier, ensuring safety and minimizing risks associated with its use. They should be willing to commit to a long-term treatment plan that includes regular monitoring by healthcare professionals, adjustments to their lifestyle, and adherence to a reduced-calorie diet paired with increased physical activity.

Before starting Wegovy, a thorough evaluation by a healthcare provider is essential to assess its suitability based on the patient's medical history, current health status, and weight management needs. This collaborative approach ensures that those who choose Wegovy are well-informed and supported throughout their treatment, maximizing the potential for successful, sustainable weight loss.

Find Out If You're Eligible Today With Mochi Health

At Mochi Health, we understand that each patient's journey towards achieving their weight management goals is unique. Our team of medical professionals and obesity medicine experts is dedicated to providing personalized support coupled with science-backed insights and comprehensive care. Mochi Health offers access to various medications, including GLP-1s, and a personalized obesity medicine program designed around your needs.

Take the first step in your weight management adventure with us. Learn more about our services and discover if you’re eligible for our innovative weight loss program today.

Sources:

1. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 70(1), 5–13. https://doi.org/10.1136/jim-2021-001952
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
3. Food and Drug Administration. (n.d.). Wegovy (semaglutide) injection, for subcutaneous use. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf 
4. Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., de Boer, A. S., Manova, K., Barlas, A., Vundavalli, S., Nyborg, N. C., Knudsen, L. B., Moelck, A. M., & Fagin, J. A. (2012). GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology, 153(3), 1538–1547. https://doi.org/10.1210/en.2011-1864
5. Nagendra, L., Bg, H., Sharma, M., & Dutta, D. (2023). Semaglutide and cancer: A systematic review and meta-analysis. Diabetes & metabolic syndrome, 17(9), 102834. https://www.sciencedirect.com/science/article/abs/pii/S1871402123001303?via%3Dihub
6. Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J., Nauck, M.A., 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obesity & Metabolism, 19:336e347. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.12824

‍